TELA BIO INC

Telabio cuts 20% of staff and shuffles leadership to save $17 M annually, aiming to stabilize finances while advancing its soft‑tissue reconstruction tech.

First‑quarter 2026 results show Tela Bio’s modest revenue growth, European market expansion and U.S. launch of OviTex LTR hernia repair, while highlighting volatility and profitability challenges.

Tela Bio Inc’s stock price has experienced significant volatility, raising concerns about the company’s financial stability and future prospects in the biotech sector.